natgillin/translations-raw huggingface dataset:
Use of the 2-propylsulphate of clopidogrel of the following formula or the perchlorate of clopidogrel of the following formula as intermediate in the preparation of clopidogrel hydrogen sulfate of form 1. 
Upotreba 2-propilsulfata klopidogrela sljedeće formule [image] ili perklorata klopidogrela sljedeće formule [image] naznačena time što se navedene spojeve upotrebljava kao međuprodukte u dobivanju oblika 1 klopidogrel-hidrogensulfata.
Z is an heteroaryl ring selected from the group consisting of: 
Z je heteroarilni prsten odabran iz skupine koja sadrži:
unsubstituted tetrazole and triazole, pyrazole, isooxazole, isothiazole, thiadiazole and oxadiazole substituted by one hydroxy group and optionally further substituted by one or more groups selected from the group consisting of halogen, linear or branched C1-C4-alkyl, C1-C4-alkylthio and halo-C1-C3-alkyl. 
nesupstituirani tetrazol i triazol, pirazol, izooksazol, izotiazol, tiadiazol i oksadiazol supstituiran sa jednom hidroksi skupinom i opcijski dalje supstituiran s jednom ili više skupina odabranih iz skupine koja sadrži halogen, ravni ili razgranati C1-C4-alkil, C1-C4-alkiltio i halo-C1-C3-alkil.
Compounds according to claims 1 or 2, wherein: Y is H or a residue selected from the group consisting of trifluoromethyl, chlorine, methyl and tert-butyl. 
Spojevi prema zahtjevima 1 ili 2, naznačeni time, da Y je H ili ostatak odabran iz skupine koja sadrži trifluorometil, klor, metil i tert-butil.
Compounds according to claims 1 to 3, wherein said triazole, pyrazole, isooxazole, isothiazole, thiadiazole or oxadiazole ring is substituted by one hydroxy group and optionally further substituted by one or more groups selected from the group consisting of methyl, trifluoromethyl and chlorine. 
Spojevi prema zahtjevima 1 do 3, naznačeni time, da spomenuti prsten triazola, pirazola, izooksazola, izotiazola, tiadiazola ili oksadiazola je supstituiran jednom hidroksi skupinom i opcijski je dalje supstituiran s jednom ili više skupina odabranih iz skupine koja sadrži metil, trifluorometil i klor.
Compounds according to claims 1 to 4, selected from the group consisting of: 
Spojevi prema zahtjevima 1 do 4, naznačeni time, da su odabrani iz skupine koja sadrži:
Compounds according to any of Claims 1 to 7 for use in the treatment of autoimmune hemolytic anemia (AIHA), psoriasis, bullous pemphigoid, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of injury caused by ischemia and reperfusion. 
Spojevi prema bilo kojem zahtjevu 1 do 7, naznačeni time, da se koriste u liječenju autoimune hemolitičke anemije (AIHA), psorijaze, buloznog pemfigoida, reumatoidnog artritisa, ulcerativnog kolitisa, sindroma akutnog respiratornog poremećaja, idiopatske fibroze, glomerulonefritisa i kod prevencije i liječenja ozljeda prouzročenih ishemijom i reperfuzijom.
Process for the preparation of compounds of claim 1, wherein Z is tetrazole, comprising the reaction of compound of formula (II), wherein X and Y have the same meaning as defined in claim 1, with trimethylsilylazide, affording the corresponding tetrazoles of formula (I). 
Postupak priprave spojeva prema zahtjevu 1, naznačen time, da Z je tetrazol, te da postupak obuhvaća reakciju spoja formule (II) [image] gdje X i Y imaju isto značenje kao što je određeno u zahtjevu 1, sa trimetilsilazidom, pribavljajući odgovarajuće tetrazole formule (I).
A polypeptide according to formula (I): 
Polipeptid prema formuli (I):
A method to produce a polypeptide comprising the steps of culturing the cell of claim 11 and purifying the expressed polypeptide. 
Postupak za dobivanje polipeptida naznačen time da sadrži korake uzgoja stanice prema zahtjevu 11 i pročišćavanja eksprimiranog polipeptida.
Process for the production of Daptomycin by fermentation of Streptomyces roseosporus in the presence of n-decanal or Cuphea oil as sources of the n-decanoyl side chain. 
Postupak proizvodnje daptomicina, naznačen time da se provodi fermentacija sa Streptomyces roseosporus u prisutnosti n-dekanala ili ulja Cuphea kao izvora n-dekanoilnog bočnog lanca.
The process according to claim 1 wherein the source of the n-decanoyl side chain is n-decanal. 
Postupak prema patentnom zahtjevu 1, naznačen time da izvor n-dekanoilnog bočnog lanca jest n-dekanal.
The process according to claim 1 wherein the source of the n-decanoyl side chain is Cuphea oil. 
Postupak prema patentnom zahtjevu 1, naznačen time da izvor n-dekanoilnog bočnog lanca jest ulje Cuphea.
dissolving lyophilized thrombin in liquid alpha-MEM and then mixing 1 to 100 IU/mL of the dissolved thrombin with the osteoblast mixed solution, and dissolving lyophilized fibrinogen in liquid alpha-MEM and then mixing 20 mg/mL to 100 mg/mL of the dissolved fibrinogen with the osteoblast mixed solution containing thrombin mixed therein. 
otapanje liofiliziranog trombina u tekućem alfa-MEM i nakon toga miješanje 1 do 100 IU/mL otopljenog trombina sa izmiješanom otopinom osteoblasta, te otapanje liofiliziranog fibrinogena u tekućem alfa-MEM i nakon toga miješanje 20 mg/mL do 100 mg/mL otopljenog fibrinogena sa izmiješanom otopinom osteoblasta koja sadrži u njoj izmiješan trombin.
A heating device for a container of a liquid pharmaceutical product having a viscosity of 50-500 cP at 4°C and contained within a glass container, comprising a substantially rigid, thin-walled housing defining an openable chamber for receiving the container, a heat source in the chamber comprising a hermetically sealed package containing a super-cooled metal salt fluid or liquid and an actuator for activating the super-cooled metal salt to produce heat, wherein the ratio of the volume of the metal salt to the intended volume of the product is no more than 1:1. 
Grijač za spremnik tekućeg farmaceutskog proizvoda, viskoziteta od 50-500 cP pri, koji se nalazi unutar staklenog spremnika, obuhvaća čvrsto kućište tankih stijenki koje definira komoru koja se može otvoriti da bi se umetnuo spremnik, izvor topline u komori koji se sastoji od hermetički zatvorenog paketa koji sadrži super-ohlađeni fluid ili tekućinu metalne soli i aktivator koji potiče super-ohlađenu metalnu sol da proizvodi toplinu, gdje omjer volumena metalne soli prema željenom volumenu proizvoda nije veći od 1:1.
A heating device as claimed in claim 1, wherein the heat source defines a cavity for receiving the container with a close fit. 
Grijač prema zahtjevu 1, gdje izvor topline definira šupljinu za zaprimanje spremnika uz skoro točno podudaranje veličina.
A heating device as claimed in claim 1 or claim 2, wherein the actuator is integral with the heat source. 
Grijač prema zahtjevu 1 ili zahtjevu 2, gdje je aktivator sastavni dio izvora topline.
A heating device as claimed in claim 3 or claim 4, wherein the actuator is positioned so as to be accessible when the container is received within the heat source and the housing is in an open position. 
Grijač prema zahtjevu 3 ili zahtjevu 4, gdje je aktivator smješten tako da bude dostupan kada se spremnik stavi unutar izvora topline i kada je kućište otvoreno.
The heating device as claimed in claim 14, wherein the insulation is integral with the tubing. 
Grijač prema zahtjevu 14, gdje je izolacija sastavni dio cijevi.
forming a biphasic composition comprising (i) a first organic phase, and (ii) an alcoholic-caustic phase containing the trans-(-)-Δ9-tetrahydrocannabinol and the trans-(+)-Δ9-tetrahydrocannabinol; 
formiranje bifaznog sastava koji sadrži (i) prvu organsku fazu, i (ii) alkoholno-kaustičnu fazu koja sadrži trans-(-)-Δ9-tetrahidrokanabinol i trans-(+)-Δ9-tetrahidrokanabinol;
forming a biphasic composition comprising (i) a first organic phase, and (ii) an alcoholic-caustic phase containing the trans-(-)-Δ9-tetrahydrocannabinol or the trans-(+)-Δ9-tetrahydrocannabinol; 
formiranje bifaznog sastava koji sadrži (i) prvu organsku fazu, i (ii) alkoholno-kaustičnu fazu koja sadrži trans-(-)-Δ9-tetrahidrokanabinol i trans-(+)-Δ9-tetrahidrokanabinol;
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropidin. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) klorotalonil.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropidin. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbomen-5-il)amid, a kao komponentu (B) klorotalonil.
at least one active agent selected from opioid analgesics wherein the opioid analgesic is hydromorphone hydrochloride and the dosage form comprises from 1 mg to about 100 mg of hydromorphone hydrochloride; and wherein the composition comprises at least about 80 % (by wt) polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000. 
barem jedan aktivni agens odabran od opioidnih analgetika gdje je opioidni analgetik oksikodon hidroklorid i oblik davanja sadrži od 5 mg do 500 mg oksikodon hidroklorida; i gdje sastav sadrži barem oko 80 % (težine) polietilen oksida koji ima, na osnovu reoloških mjerenja, prosječnu molekularnu težinu od barem 1.000.000.
A pharmaceutical tablet in accordance with any one of the preceding claims having (a) a cracking force of at least 110 N, preferably 120 N, more preferably 130 N, and even more preferably 140 N, when subjected to an indentation test; (b) a penetration depth to crack distance of at least 1.0 mm, preferably 1.2 mm, more preferably 1.4 mm, and even more preferably 1.6 mm, when subjected to an indentation test; and (c) capable of resisting a work of at least 0.06 J without cracking. 
Farmaceutska tableta prema bilo kojem prethodnom zahtjevu, naznačena time da ima (a) snagu pucanja od barem 110 N, poželjno 120 N, poželjnije 130 N, i još poželjnije 140 N, kada je podvrgnuta indentacijskom testu; (b) dubinu prodiranja s razmakom pukotine od barem 1,0 mm, poželjno 1,2 mm, poželjnije 1,4 mm, i još poželjnije 1,6 mm, kada je podvrgnuta indentacijskom testu; i (c) sposobnost da se odupre radu od najmanje 0,06 J bez pucanja.
Ready-meal package (1) according to one of the preceding claims, wherein the main container (2), the secondary container (3) and the covering means (4) are made of material specifically intended for use in microwaves. 
Paket gotove hrane (1) prema jednom od prethodnih zahtjeva, gdje su glavni spremnik (2), sekundarni spremnik (3) i sredstva za pokrivanje (4) napravljeni od materijala koji je specifično namijenjen za uporabu u mikrovalnoj pećnici.
demodulating the received signal frame by an Orthogonal Frequency Division Multiplexing(OFDM) method; 
demodulaciju primljenog signalnog okvira korištenjem metode multipleksiranja s ortogonalnom podjelom frekvencija (OFDM);
means for demodulating the received signal frame by an Orthogonal Frequency Division Multiplexing(OFDM) method; 
sredstva za demodulaciju primljenog signalnog okvira korištenjem metode multipleksiranja s ortogonalnom podjelom frekvencija (OFDM);
The apparatus of claim 13 or 14, wherein the L1 block has 1.1 signaling information for signaling the data slice. 
Uređaj prema zahtjevu 11 ili 12, naznačen time, što L1 blok ima L1 signalizacijsku informaciju za signaliziranje podatkovnog odsječka.
An immunogenic composition comprising a non-replicating or replication impaired poxvirus vector expressing the translation product of a mycobacterial Ag85A gene for use in preventing mycobacterial infection or disease by inducing a central memory T cell immune response in a patient, wherein the viral vector expresses Ag85A with a PK C-terminus tag, a TPA leader sequence, and a C-terminal truncation of 10-20 amino acids and wherein said immune response persists for at least 1 year. 
Imunogena smjesa koja sadrži poxvirus kao ne-replicirajući vektor, ili vektor s poremećajem replikacije, koji eksprimira produkt translacije mikobakterijskog Ag85A gena, za uporabu u prevenciji zaraze mikobakterijom ili bolesti tako što kod bolesnika inducira T stanični središnji memorijski imuni odgovor, pri čemu virusni vektor eksprimira Ag85A s PK označenim C-krajem, TPA vodećom sekvencom i skraćenim C-krajem za 10-20 aminokiselina i pri čemu spomenuti imuni odgovor traje najmanje 1 godinu.
Use of an immunogenic composition comprising a non-replicating or replication impaired poxvirus vector expressing the translation product of a mycobacterial Ag85A gene in the manufacture of a medicament for the prevention of a mycobacterial infection or disease in a patient by inducing a central memory T cell immune response in the patient, wherein the viral vector expresses Ag85A with a PK C-terminus tag, a TPA leader sequence and a C-terminal truncation of 10-20 amino acids and wherein said immune response persists for at least 1 year. 
Uporaba imunogene smjese koja sadrži poxvirus kao ne-replicirajući vektor, ili vektor s poremećajem replikacije, koji eksprimira produkt translacije mikobakterijskog Ag85A gena, za proizvodnju lijeka za prevenciju zaraze mikobakterijom ili bolesti tako što kod bolesnika inducira T stanični središnji memorijski imuni odgovor, pri čemu virusni vektor eksprimira Ag85A s PK označenim C-krajem, TPA vodećom sekvencom i skraćenim C-krajem za 10-20 aminokiselina i pri čemu spomenuti imuni odgovor traje najmanje 1 godinu.
The composition or use of claim 5 wherein the at least one additional antigen and/or antimicrobial is for administration simultaneously, separately or sequentially. 
Smjesa ili uporaba prema zahtjevu 5, pri čemu se najmanje jedan dodatni antigen i/ili antimikrobno sredstvo primjenjuje istodobno, odvojeno ili uzastopno.
Use according to claim 2, wherein the viral vector additionally expresses the translation product of at least one additional antigen gene for the prevention of at least one additional disease in a patient. 
Uporaba prema zahtjevu 2, gdje virusni vektor dodatno eksprimira produkt translacije najmanje jednog dodatnog gena antigena, za prevenciju najmanje jedne dodatne bolesti kod bolesnika.
The immunogenic composition of claim 1 or use of claim 2 wherein the medicament is to be administered with at least one additional antigen, further for use in treating or preventing at least one disease selected from the group consisting of tuberculosis, leprosy, Mycobacterium avium infection, non-tuberculosis mycobacterial infection, Buruli ulcer, Mycobacterium bovis infection or disease, smallpox, monkeypox, Mycobacterium paratuberculosis infection, inflammatory bowel disease, Crohns Disease, autoimmune disease, cancer and bladder cancer. 
Imunogena smjesa prema zahtjevu 1 ili uporaba prema zahtjevu 2, gdje se lijek primjenjuje s najmanje jednim dodatnim antigenom, dalje za uporabu u liječenju ili prevenciji najmanje jedne bolesti izabrane iz skupine koja obuhvaća tuberkulozu, lepru, zarazu s Mycobacterium avium, ne-tuberkuloznu mikobakterijsku zarazu, Buruli čir, zarazu ili bolest Mycobacterium bovis, male boginje, boginje majmuna, zarazu s Mycobacterium paratuberculosis, upalnu bolest crijeva, Crohnovu bolest, autoimunu bolest, rak i rak mjehura.
The immunogenic composition or use of any preceding claim, wherein the patient is selected from the group consisting of children, patients who have HIV infection or AIDS, are immunocompromised or have undergone organ transplants. 
Imunogena smjesa ili uporaba prema bilo kojem prethodnom zahtjevu, gdje se bolesnik izabire iz skupine koja obuhvaća djecu, bolesnike zaražene HIV-om ili bolesnike koji boluju od AIDS-a, imunokompromitirane bolesnike ili one koji su imali transplantaciju organa.
The vectored vaccine of claim 15 or claim 16, wherein the non-replicating viral vector is MVA. 
Vektorsko cjepivo prema zahtjevu 15 ili prema zahtjevu 16, gdje je ne-replicirajući virusni vektor MVA.
said monoclonal antibody is the monoclonal anti idiotypic anti-CA-125 MEN 2234 comprising SEQ. 
navedeno monoklonsko antitijelo je monoklonsko antiidiotipsko anti-CA-125 MEN 2234 antitijelo koje uključuje SEQ.
2 and is present in an amount from 0.1-4 mg/ml and adsorbed onto the aluminium derivative; and said aluminium compound is chosen among aluminium hydroxide and aluminium phosphate and is suspended in an aqueous buffered system; characterised in that said pharmaceutical composition contains 1 ml of the product to be administered. 
2, i prisutno je u količini od 0.1-4 mg/ml, i adsorbirano je na derivat aluminija; i navedeni aluminijski spoj bira se između aluminijskog hidroksida i aluminijskog fosfata i suspendirano je u vodenom puferiranom sustavu; gdje navedena farmaceutska smjesa sadrži 1 ml proizvoda za primjenu.
Pharmaceutical composition according to claims 3 wherein the MEN2234 is present in an amount from 0.2 - 2.5 mg/ml 
Farmaceutska smjesa prema zahtjevu 3, naznačena time, što je MEN 2234 prisutan u količini od 0.2-2.5 mg/ml.
Pharmaceutical composition according to claim 4, wherein MEN2234 is present in an amount from 1.9 to 2.1 mg/ml 
Farmaceutska smjesa prema zahtjevu 4, naznačena time, što je MEN 2234 prisutan u količini od 1.9 do 2.1 mg/ml.
Pharmaceutical composition according to claims 1-5, wherein MEN2234 is adsorbed onto the aluminium compound and suspended in a buffered and isotonic saline solution. 
Farmaceutska smjesa prema zahtjevima 1-5, naznačena time, što je MEN 2234 adsorbiran na aluminijski spoj i suspendiran u puferiranoj i izotoničnoj slanoj otopini.
Pharmaceutical composition according to claims 1-6, in the form of a liquid suspension, suitable for parenteral administration. 
Farmaceutska smjesa prema zahtjevima 1-6, naznačena time, što je u formi tekuće suspenzije pogodne za parenteralnu primjenu.
Pharmaceutical composition according to Claims 1 - 8, selected among the following: 
Farmaceutska smjesa prema zahtjevima 1-8, naznačena time, što se bira od slijedećeg:
Pharmaceutical composition according to claim 10 as antitumoral vaccine for the treatment of ovarian tumours. 
Farmaceutska smjesa prema zahtjevu 10, naznačena time, što je antitumorsko cjepivo za liječenje tumora ovarija.
Pirfenidone for use in treating a patient with idiopathic pulmonary fibrosis (IPF), said patient having exhibited a Grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration, said patient having exhibited an abnormal level of alanine transaminase (ALT) and/or aspartate transaminase (AST) that is greater than 2.5- to 5-fold increased compared to the upper limit of normal, after pirfenidone administration, wherein (a) said patient is administered pirfenidone at doses of at least 1600 mg/day or 1602 mg/day. 
Pirfenidon za upotrebu u liječenju pacijenta s idiopatskom pulmonarnom fibrozom (IPF), pri čemu pacijent ima razinu 2 abnormalnosti u jednom ili više biomarkera funkcije jetre poslije davanja pirfenidona, i ima abnormalnu razinu alanin transaminaze (ALT) i/ili aspartat transaminaze (AST) koja je više od 2.5- do 5.0 –puta povećana u usporedbi s gornjom normalnom vrijednošću, poslije davanja pirfenidona, gdje (a) spomenutom pacijentu se daje pirfenidon u dozama od bar 1600 mg/dan ili 1602 mg/dan.
Pirfenidone for use in treating a patient with idiopathic pulmonary fibrosis (IPF), said patient having exhibited a Grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration, said patient having exhibited an abnormal level of alanine transaminase (ALT) and/or aspartate transaminase (AST) that is greater than 2.5- to 5-fold increased compared to the upper limit of normal, after pirfenidone administration, wherein (a) said patient is administered pirfenidone at doses of 2400 mg/day or 2403 mg/day. 
Pirfenidon za upotrebu u liječenju pacijenta s idiopatskom pulmonarnom fibrozom (IPF), pri čemu pacijent ima razinu 2 abnormalnosti u jednom ili više biomarkera funkcije jetre poslije davanja pirfenidona, i ima abnormalnu razinu alanin transaminaze (ALT) i/ili aspartat transaminaze (AST) koja je više od 2.5- do 5.0 –puta povećana u usporedbi s gornjom normalnom vrijednošću, poslije davanja pirfenidona, gdje (a) spomenutom pacijentu se daje pirfenidon u dozama od bar 2400 mg/dan ili 2403 mg/dan.
Use of pirfenidone in the manufacture of a medicament for treating a patient with idiopathic pulmonary fibrosis (IPF), said patient having exhibited a Grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration, said patient having exhibited an abnormal level of alanine transaminase (ALT) and/or aspartate transaminase (AST) that is greater than 2.5- to 5-fold increased compared to the upper limit of normal, after pirfenidone administration, wherein (a) said patient is administered pirfenidone at doses of at least 1600 mg/day or 1602 mg/day. 
Upotreba pirfenidona u proizvodnji lijeka za liječenje pacijenta s idiopatskom pulmonarnom fibrozom (IPF), pri čemu pacijent ima razinu 2 abnormalnosti u jednom ili više biomarkera funkcije jetre poslije davanja pirfenidona, i ima abnormalnu razinu alanin transaminaze (ALT) i/ili aspartat transaminaze (AST) koji je više od 2.5- do 5- puta povećana u usporedbi s gornjom granicom normalnih vrijednosti, poslije davanja pirfenidona, gdje (a) spomenutom pacijentu je davan pirfenidon u dozama od bar 1600 mg/dnevno ili 1602 mg/dnevno.
Printing sheet for offset printing, comprising at least one image receiving coating and optionally one or several pre-coatings beneath said image receiving coating, said coatings comprising a pigment part, a binder part, and optionally additives, wherein the pigment part essentially comprises one or a mixture of fine particulate pigments selected from the group of carbonate, kaolin, gypsum, clay, silica, solid or vacuolated polymer pigment, wherein said binder part comprises waterglass, characterized in that the weight ratio of SiO2:Na2O in the waterglass is above or equal to 3.2. 
List papira za offset tisak, koji se sastoji od najmanje jednog premaza koji prima sliku i proizvoljno jednog ili nekoliko prethodnih-premaza ispod navedenog premaza koji prima sliku, te navedeni premazi sadrže pigmentni dio, vezivni dio, i proizvoljno aditive, pri čemu pigmentni dio u osnovi sadrži jedan pigment ili mješavinu sitnih čestica pigmenata odabranu iz skupine karbonata, kaolina, gipsa, gline, silicij-dioksida, krutog polimernog pigmenta ili koji sadrži sitne šupljine, pri čemu navedeni vezivni dio sadrži vodeno staklo, naznačen time da je težinski omjer SiO2:Na2O u vodenom staklu veći ili jednak 3.2.
Printing sheet according to any of the preceding claims, wherein at least 50%, preferably at least 75% of the dry weight of the pigment part consists of a carbonate and/or kaolin pigment. 
List papira za ispis prema bilo kojem od prethodnih zahtjeva, naznačen time da najmanje 50%, poželjno najmanje 75% mase suhe tvari pigmentnog dijela se sastoji od karbonatnog i/ili kaolinskog pigmenta.